BRPI0924427A2 - controlled release pharmaceutical composition, its preparation process and its use - Google Patents

controlled release pharmaceutical composition, its preparation process and its use

Info

Publication number
BRPI0924427A2
BRPI0924427A2 BRPI0924427A BRPI0924427A BRPI0924427A2 BR PI0924427 A2 BRPI0924427 A2 BR PI0924427A2 BR PI0924427 A BRPI0924427 A BR PI0924427A BR PI0924427 A BRPI0924427 A BR PI0924427A BR PI0924427 A2 BRPI0924427 A2 BR PI0924427A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparation process
controlled release
release pharmaceutical
controlled
Prior art date
Application number
BRPI0924427A
Other languages
Portuguese (pt)
Inventor
Gerhard Renner
Hans Bär
Michael Gottschalk
Thomas Fürst
Thomas Rupp
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of BRPI0924427A2 publication Critical patent/BRPI0924427A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0924427A 2009-03-18 2009-03-18 controlled release pharmaceutical composition, its preparation process and its use BRPI0924427A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/053177 WO2010105673A1 (en) 2009-03-18 2009-03-18 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients

Publications (1)

Publication Number Publication Date
BRPI0924427A2 true BRPI0924427A2 (en) 2016-01-26

Family

ID=40752823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924427A BRPI0924427A2 (en) 2009-03-18 2009-03-18 controlled release pharmaceutical composition, its preparation process and its use

Country Status (10)

Country Link
US (1) US20110311631A1 (en)
EP (1) EP2408437A1 (en)
JP (1) JP5619131B2 (en)
KR (1) KR20120003436A (en)
CN (1) CN102365083A (en)
BR (1) BRPI0924427A2 (en)
CA (1) CA2755814A1 (en)
IL (1) IL214612A0 (en)
MX (1) MX2011009669A (en)
WO (1) WO2010105673A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE042593T2 (en) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alcohol-resistant enteral formulations
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
KR20130030260A (en) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. Pharmaceutical compositions comprising hydromorphone and naloxone
CN103501768B (en) 2011-06-17 2016-11-09 赢创罗姆有限公司 There is the gastric resistant pharmaceutical or nutraceutical composition of anti-influence of ethanol resistance
MX353427B (en) * 2011-06-17 2018-01-12 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms.
JP5832645B2 (en) 2011-06-17 2015-12-16 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ Coating compositions suitable for pharmaceutical or nutritional supplement forms
FR2986431B1 (en) * 2012-02-03 2017-03-17 Servier Lab PROLONGED RELEASE OF TRIMETAZIDINE PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PRODUCTION THEREOF AND USE IN THERAPEUTIC TREATMENTS
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN105050708A (en) 2012-11-14 2015-11-11 格雷斯公司 Compositions containing bioactive materials and disordered inorganic oxides
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US10053597B2 (en) 2013-01-18 2018-08-21 Basf Se Acrylic dispersion-based coating compositions
JP6150564B2 (en) * 2013-03-08 2017-06-21 杏林製薬株式会社 Orally rapidly disintegrating tablets
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106727435B (en) * 2016-12-26 2020-06-02 浙江工业大学 Metoprolol sustained-release capsule and preparation method thereof
US11554114B2 (en) * 2017-03-31 2023-01-17 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredients
KR20200057019A (en) 2017-09-14 2020-05-25 에보닉 오퍼레이션스 게엠베하 Polymers and dosage forms with sustained release and resistance to the effects of ethanol
KR102810926B1 (en) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 Abuse-deterrent morphine sulfate formulation
JP2021515778A (en) 2018-03-09 2021-06-24 エボニック オペレーションズ ゲーエムベーハー Polymer mixture resistant to the effects of ethanol
KR102138253B1 (en) * 2018-08-17 2020-07-29 한국유나이티드제약 주식회사 Sustained release preparation of cilostazol
BR112021006027A2 (en) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited alcohol resistant drug formulations
TW202139986A (en) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 Methods of treating idiopathic hypersomnia
EP4142668A1 (en) * 2020-04-30 2023-03-08 Kindeva Drug Delivery L.P. Adhesive article and method of making same
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
CN112294777B (en) * 2020-11-04 2022-07-05 南京康川济医药科技有限公司 Ivabradine hydrochloride sustained-release preparation and preparation method and application thereof
WO2023280962A1 (en) * 2021-07-09 2023-01-12 Evonik Operations Gmbh Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants
CN113925838B (en) * 2021-11-11 2022-11-11 乐普制药科技有限公司 Compound sustained-release tablet of epalrestat and sitagliptin or pharmaceutically acceptable salt thereof and preparation method thereof
JPWO2023224097A1 (en) * 2022-05-18 2023-11-23

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (en) * 1989-12-05 1992-04-03 Smith Kline French Lab CIMETIDINE PHARMACEUTICAL COMPOSITIONS.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU5775398A (en) * 1996-12-17 1998-07-15 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
DE19918435A1 (en) * 1998-07-23 2000-01-27 Roehm Gmbh Coating or binding agent for medicaments, prepared using finely divided acrylic copolymer powder, used e.g. for taste-masking coatings or in transdermal delivery systems
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10208335A1 (en) * 2002-02-27 2003-09-04 Roehm Gmbh Pharmaceutical form and process for its preparation
AU2003270349A1 (en) * 2002-09-09 2004-03-29 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
DE10250543A1 (en) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Multilayer dosage form
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2543689A1 (en) * 2003-10-31 2005-05-12 Hexal Ag Pharmaceutical actve-ingredient-containing formulation with coating
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
DE102005024614A1 (en) * 2005-05-25 2006-11-30 Röhm Gmbh Use of polymer blends for the production of coated drug forms and drug form with polymeric blend coating
SG169334A1 (en) * 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
DE102006051020A1 (en) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Use of (meth) acrylate copolymers in sustained release dosage forms to reduce the effect of ethanol on drug release
CA2923102C (en) * 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Abuse resistant drugs, method of use and method of making
MX2010003032A (en) * 2007-09-21 2010-04-09 Evonik R Hm Gmbh Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol.

Also Published As

Publication number Publication date
CN102365083A (en) 2012-02-29
CA2755814A1 (en) 2010-09-23
JP5619131B2 (en) 2014-11-05
JP2012520832A (en) 2012-09-10
IL214612A0 (en) 2011-09-27
US20110311631A1 (en) 2011-12-22
KR20120003436A (en) 2012-01-10
MX2011009669A (en) 2011-12-14
EP2408437A1 (en) 2012-01-25
WO2010105673A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
BR112012003842A2 (en) pharmaceutical composition, method of formulation and use thereof
BR112012006404A2 (en) dihydropteridinone derivatives, their preparation process and their pharmaceutical use
BRPI1009372A2 (en) compounds, pharmaceutical composition and their uses
BRPI1010621A2 (en) imidazoquinolinones derivative, their pharmaceutical composition and their use
BR112013011968A2 (en) pharmaceutical composition, treatment methods and uses thereof
BRPI1016219A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI1008793A2 (en) compound use of a compound and pharmaceutical composition
BRPI1009481A2 (en) substituted 2-acetamido-5-aryl-1,2,4-triazolones compounds, their preparation process, their use and medicament comprising the same
BR112013016772A2 (en) compound, compound use, pharmaceutical composition, oligonucleotide and conjugate
BRPI1007018A2 (en) compound, pharmaceutical composition, and use of a compound.
BRPI0919466A2 (en) modified release pharmaceutical composition
BRPI1008045A2 (en) aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
BRPI1009324A2 (en) and / or pharmaceutically acceptable compounds thereof, pharmaceutical composition and their uses
BRPI0912356A2 (en) sirtuin modulating compounds, pharmaceutical composition comprising them and their use
PT2590976E (en) IMITAZOPYRIDINE DERIVATIVES, ITS PREPARATION PROCESS AND ITS THERAPEUTIC USE
BRPI1008906A2 (en) compound, pharmaceutical composition, and use of a compound.
CL2014000732A1 (en) Heterocyclic derivative compounds for use in the prevention or treatment of a flavivirus infection; method for its preparation; and pharmaceutical composition that includes them.
CL2008000403A1 (en) COMPOUNDS DERIVED FROM PENTAFLUOROTIOBENZAMIDO-ACETONITRILO; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT AN INFRASTATION BY PARASITES.
BRPI1014606A2 (en) Maltotriosil transferase, process for production and use thereof
BR112012022879A2 (en) compound, pharmaceutical composition, compound use and treatment method
BR112012031226A2 (en) compound, compound use, pharmaceutical composition, and pharmaceutical composition use
DK2391349T3 (en) Pharmaceutical composition comprising 2-oco-1-pyrrolidine derivatives
BRPI1009757A2 (en) compound, pharmaceutical composition, and use of a compound.
BRPI1011412A2 (en) sustained release drug composition comprising geopolymeric alutinant
BRPI0822946A2 (en) Carboxyamide derivative, process for preparing carboxyamide derivative, pharmaceutical composition and use of carboxyamide derivative

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]